- 23620310OWN - NLMSTAT- MEDLINEDA  - 20140303DCOM- 20140424IS  - 1940-1574 (Electronic)IS  - 0003-3197 (Linking)VI  - 65IP  - 4DP  - 2014 AprTI  - Milrinone in advanced heart failure: dose and therapeutic monitor outside      intensive care unit.PG  - 343-9LID - 10.1177/0003319713485808 [doi]AB  - Advanced chronic heart failure (ACHF) patients often require inotropes before      transplantation or ventricular assist device implantation. Milrinone, an inotrope      and vasodilator, may accumulate in cardiorenal syndrome with serious adverse      effects. We investigated the potential for therapeutic drug monitoring of      milrinone levels using High Performance Liquid Chromatography Mass Spectrometry      (HPLC-MS). 22 ACHF patients (15 males, 49+/-9 years) received milrinone 50      microg/kg intravenously (i.v.) during heart catheterization. Milrinone levels      were 216+/-71 ng/ml (within the reported therapeutic range: 100-300 ng/ml),      followed by improvements in cardiac index, pulmonary artery and wedge pressures      (p < 0.005). 18 ACHF patients (17 males, 50+/-12 years, 13 had renal dysfunction)      received continuous i.v. milrinone (5-26 days) at 0.1-0.2 microg/kg/min, titrated      according to plasma milrinone levels. No adverse events occurred. Therapeutic      levels were achieved with doses of 0.2+/-0.06 microg/Kg/min, below those      recommended in Summary of Product Characteristics. Milrinone therapy can be      noninvasively monitored by HPLC-MS, while avoiding toxicity in ACHF.FAU - Charisopoulou, DafniAU  - Charisopoulou DAD  - 1Royal Brompton and Harefield NHS Trust, UK.FAU - Leaver, NeilAU  - Leaver NFAU - Banner, Nicholas RAU  - Banner NRLA  - engPT  - Journal ArticlePT  - Research Support, Non-U.S. Gov'tDEP - 20130425PL  - United StatesTA  - AngiologyJT  - AngiologyJID - 0203706RN  - 0 (Cardiotonic Agents)RN  - 0 (Vasodilator Agents)RN  - JU9YAX04C7 (Milrinone)SB  - IMMH  - AdultMH  - Cardiac CatheterizationMH  - Cardiotonic Agents/*administration & dosage/adverse effects/bloodMH  - *Chromatography, High Pressure LiquidMH  - Chronic DiseaseMH  - Drug Dosage CalculationsMH  - Drug Monitoring/*methodsMH  - FemaleMH  - Heart Failure/diagnosis/*drug therapy/physiopathologyMH  - Hemodynamics/drug effectsMH  - HumansMH  - Infusions, IntravenousMH  - MaleMH  - *Mass SpectrometryMH  - Middle AgedMH  - Milrinone/*administration & dosage/adverse effects/bloodMH  - Treatment OutcomeMH  - Vasodilator Agents/*administration & dosage/adverse effects/bloodOTO - NOTNLMOT  - advanced chronic heart failureOT  - high-performance liquid chromatography mass spectrometryOT  - inotropesOT  - milrinoneOT  - renal failureEDAT- 2013/04/27 06:00MHDA- 2014/04/25 06:00CRDT- 2013/04/27 06:00PHST- 2013/04/25 [aheadofprint]AID - 0003319713485808 [pii]AID - 10.1177/0003319713485808 [doi]PST - ppublishSO  - Angiology. 2014 Apr;65(4):343-9. doi: 10.1177/0003319713485808. Epub 2013 Apr 25.